Sumitomo Pharma Co., Ltd. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
SMDPY Over the counter 3850 www.sumitomo-pharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sumitomo Pharma Co., Ltd.

2026 Assessment of the Nuvisertib Market: Sales Forecasts, Clinical Differentiation, Competitive Threats, and Commercial Opportunities Through 2034 - Sep 10th, 2026 4:45 am
Sumitomo Pharma (TSE:4506) Stock Looks Below Fair Value On Earnings Power - Sep 4th, 2026 9:08 am
Interest Rate, Oil, Tech Jitters Blunt Asian Stock Markets - Sep 2nd, 2026 4:41 am
Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight - Aug 18th, 2026 8:33 am
Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa - Aug 12th, 2026 6:30 am
Sumitomo Chemical Co Ltd (SOMMF) (Q1 2027) Earnings Call Highlights: Core Operating Income ... - Aug 4th, 2026 9:00 am
Bank of Japan Outlook, Beijing Economic Report Roil Asian Stock Markets - Dec 29th, 2025 3:49 am
Is Sumitomo Pharma’s 344% 2025 Surge Still Supported by Its Fundamentals? - Dec 10th, 2025 8:08 am
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition - Dec 8th, 2025 10:00 am